China Advances CRISPR Trials for Duchenne Muscular Dystrophy Amid U.S. Stagnation
Analyzed 1 source • 0m ago- GenAssist and Huidagene are leading CRISPR trials for Duchenne muscular dystrophy.
- Existing therapies like Elevidys have shown limited efficacy, increasing urgency.
- U.S. CRISPR efforts are stalling, contrasting with China's rapid progress.
- Success in these trials could revolutionize treatments for genetic disorders.
The sources of this summary are listed below. Click to view.
